Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kazi Mustafa Mahmud has a total of 21 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Multivariable Design of a Minimalist Conjugated Polymer Nanoparticle with Bright NIR‐II Emission

    by Nikita Gill, Robert Posey, Brenda Alfaro, Helena Garza, Jacquelyn Tran, Kazi Mustafa Mahmud, Annemarie C. Fritz, Tahamida Alam Oyshi, Ehsan Nozohouri, Indrajit Srivastava, et al.

    Near‐infrared (NIR) emitting materials underpin emerging medical diagnostics and therapeutic bionanotechnologies. In particular, the NIR‐II window (1000–1700 nm) allows for enhanced penetration depth and image clarity in vivo by minimizing light‐tissue interactions. Organic materials are advantageous due to their synthetic tunability; however, the energy gap law poses fundamental limitations on accessible quantum yields (Φ) due to the exponential increase in nonradiative decay rates as the bandgap narrows. Conjugated polymer nanoparticles (CPNs) offer biocompatibility, photostability, and remarkable absorption cross‐sections (ɛ), the latter of which can offset the reduced Φ of the organic material to afford brilliant emission (ɛ × Φ). Here, a structurally simple, scalable furan‐flanked diketopyrrolopyrrole material (PDFT) with peak emission at 950 nm is investigated, and the role of backbone architecture, molecular weight, and particle size on NIR‐II emission brightness are explored. PDFT CPNs features extraordinary brightness and photostability in solution and in vivo, outperforming indocyanine green and many contemporary NIR‐II emitters. Through rational structural modifications across multiple length scales, the NIR‐II brightness is enhanced >5000× beyond alternative small molecules, featuring a minimum detectable dose of 0.65 n m in vivo. This performance, combined with synthetic accessibility and scalability, positions PDFT as a promising material for NIR‐II bionanotechnologies.


  • Open Access

    The Promise of Nanoparticles-Based Radiotherapy in Cancer Treatment

    by Munima Haque, Salman Shakil, Kazi Mustafa Mahmud

    Radiation has been utilized for a long time for the treatment of cancer patients. However, radiotherapy (RT) has many constraints, among which non-selectivity is the primary one. The implementation of nanoparticles (NPs) with RT not only localizes radiation in targeted tissue but also provides significant tumoricidal effect(s) compared to radiation alone. NPs can be functionalized with both biomolecules and therapeutic agents, and their combination significantly reduces the side effects of RT. NP-based RT destroys cancer cells through multiple mechanisms, including ROS generation, which in turn damages DNA and other cellular organelles, inhibiting of the DNA double-strand damage-repair system, obstructing of the cell cycle, regulating of the tumor microenvironment, and killing of cancer stem cells. Furthermore, such combined treatments overcome radioresistance and drug resistance to chemotherapy. Additionally, NP-based RT in combined treatments have shown synergistic therapeutic benefit(s) and enhanced the therapeutic window. Furthermore, a combination of phototherapy, i.e., photodynamic therapy and photothermal therapy with NP-based RT, not only reduces phototoxicity but also offers excellent therapeutic benefits. Moreover, using NPs with RT has shown promise in cancer treatment and shown excellent therapeutic outcomes in clinical trials. Therefore, extensive research in this field will pave the way toward improved RT in cancer treatment.


  • Open Access

    Theranostic Potentials of Gold Nanomaterials in Hematological Malignancies

    by Salman Shakil, Mahruba Sultana Niloy, Kazi Mustafa Mahmud, Mohammad Amjad Kamal, Asiful Islam

    Hematological malignancies (HMs) are a heterogeneous group of blood neoplasia generally characterized by abnormal blood-cell production. Detection of HMs-specific molecular biomarkers (e.g., surface antigens, nucleic acid, and proteomic biomarkers) is crucial in determining clinical states and monitoring disease progression. Early diagnosis of HMs, followed by an effective treatment, can remarkably extend overall survival of patients. However, traditional and advanced HMs’ diagnostic strategies still lack selectivity and sensitivity. More importantly, commercially available chemotherapeutic drugs are losing their efficacy due to adverse effects, and many patients develop resistance against these drugs. To overcome these limitations, the development of novel potent and reliable theranostic agents is urgently needed to diagnose and combat HMs at an early stage. Recently, gold nanomaterials (GNMs) have shown promise in the diagnosis and treatment of HMs. Magnetic resonance and the surface-plasmon-resonance properties of GNMs have made them a suitable candidate in the diagnosis of HMs via magnetic-resonance imaging and colorimetric or electrochemical sensing of cancer-specific biomarkers. Furthermore, GNMs-based photodynamic therapy, photothermal therapy, radiation therapy, and targeted drug delivery enhanced the selectivity and efficacy of anticancer drugs or drug candidates. Therefore, surface-tuned GNMs could be used as sensitive, reliable, and accurate early HMs, metastatic HMs, and MRD-detection tools, as well as selective, potent anticancer agents. However, GNMs may induce endothelial leakage to exacerbate cancer metastasis. Studies using clinical patient samples, patient-derived HMs models, or healthy-animal models could give a precise idea about their theranostic potential as well as biocompatibility. The present review will investigate the theranostic potential of vectorized GNMs in HMs and future challenges before clinical theranostic applications in HMs.


  • Open Access

    Using Chitosan or Chitosan Derivatives in Cancer Therapy

    by Salman Shakil, Kazi Mustafa Mahmud, Mohammad Sayem, Mahruba Sultana Niloy, Sajal Kumar Halder, Sakib Hossen, Forhad Uddin, Ashraful Hasan

    Cancer is one of the major causes of death worldwide. Chemotherapeutic drugs have become a popular choice as anticancer agents. Despite the therapeutic benefits of chemotherapeutic drugs, patients often experience side effects and drug resistance. Biopolymers could be used to overcome some of the limitations of chemotherapeutic drugs, as well as be used either as anticancer agents or drug delivery vehicles. Chitosan is a biocompatible polymer derived from chitin. Chitosan, chitosan derivatives, or chitosan nanoparticles have shown their promise as an anticancer agent. Additionally, functionally modified chitosan can be used to deliver nucleic acids, chemotherapeutic drugs, and anticancer agents. More importantly, chitosan-based drug delivery systems improved the efficacy, potency, cytotoxicity, or biocompatibility of these anticancer agents. In this review, we will investigate the properties of chitosan and chemically tuned chitosan derivatives, and their application in cancer therapy.


  • Open Access

    Ruthenium Complexes: An Alternative to Platinum Drugs in Colorectal Cancer Treatment

    by Kazi Mustafa Mahmud, Mahruba Sultana Niloy, Salman Shakil, Asiful Islam

    Colorectal cancer (CRC) is one of the intimidating causes of death around the world. CRC originated from mutations of tumor suppressor genes, proto-oncogenes and DNA repair genes. Though platinum (Pt)-based anticancer drugs have been widely used in the treatment of cancer, their toxicity and CRC cells’ resistance to Pt drugs has piqued interest in the search for alternative metal-based drugs. Ruthenium (Ru)-based compounds displayed promising anticancer activity due to their unique chemical properties. Ru-complexes are reported to exert their anticancer activities in CRC cells by regulating different cell signaling pathways that are either directly or indirectly associated with cell growth, division, proliferation, and migration. Additionally, some Ru-based drug candidates showed higher potency compared to commercially available Pt-based anticancer drugs in CRC cell line models. Meanwhile Ru nanoparticles coupled with photosensitizers or anticancer agents have also shown theranostic potential towards CRC. Ru-nanoformulations improve drug efficacy, targeted drug delivery, immune activation, and biocompatibility, and therefore may be capable of overcoming some of the existing chemotherapeutic limitations. Among the potential Ru-based compounds, only Ru (III)-based drug NKP-1339 has undergone phase-Ib clinical trials in CRC treatment.